FIVE-YEAR CLINICAL EXPERIENCE WITH MENINGOCOCCAL INFECTIONS AT “SF. PARASCHEVA” INFECTIOUS DISEASES HOSPITAL DURING 2014 – 2018

  • Georgiana ENACHE-LEONTE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ioana Maria HUNEA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Adelina MATEI “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Aurelia CRETU Regional Institute of Oncology, Iasi
  • Lidia Oana STAMATEANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ioana Alina HARJA ALEXA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Mihaela Catalina LUCA “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Aim: To evaluate the epidemiological, clinical-biological and therapeutic data and to assess the influence of standard pretreatment prognosis score on the evolution on meningococcal infection. Material and methods: Retrospective analysis of the hospital-based medical records of patients with acute meningococcal infections admitted to the Iaşi Clinic of Infectious Diseases between 2014 and 2018. Selection of patients with classic clinical symptoms of meningitis was based on Gram staining, culture and latex agglutination. The risk factors for complications or death were assessed. Results: A total of 370 meningitis patients hospitalized between 2014 and 2018 were reviewed. Meningococcal infections were recorded in 8.05% cases of bacterial meningitis. CSF cultures were positive for only 60% of the study patients. Co-agglutination was clinically useful for confirming the diagnosis in 38% cases. Mortality rate was 14.3% and was related to meningococcemia. Platelet count was the most important predictor in fatal cases. The results showed a poor correlation between length of hospital stay and standard pretreatment prognostic score (r=0.201). Conclusions: Meningococcal infection remains a significant health problem because of its serious complications and high mortality rate. The results of this study highlight the importance of implementing the meningococcal immunization programs in our country.

Author Biographies

Georgiana ENACHE-LEONTE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (II)

Ioana Maria HUNEA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (II)

Adelina MATEI, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (II)

Lidia Oana STAMATEANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (II)

Ioana Alina HARJA ALEXA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (II)

Mihaela Catalina LUCA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (II)
Regional Institute of Oncology, Ias

References

1. Whittaker R, Dias JG, Ramliden M, et al. ECDC network members for invasive meningococcal disease. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine 2017; 35(16): 2034-2041.
2. Johri S, Gorthi SP, Anand AC. Meningococcal Meningitis. Med J Armed Forces India 2005; 61(4): 369-374.
3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(2): 51-63.
4. ***European Centre for Disease Prevention and Control. Indicator-based surveillance: The European Surveillance System (TESSy). Stockholm: ECDC; 2016.Available at web site: http://ecdc.europa.eu/en/activities/surveillance/ Pages/index.aspx. Accessed September 20, 2018.
5. Pelton SI. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines. J Adolesc Health 2016; 59(2): 3-11.
6. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID Study Group for Infections of the Brain (ESGIB). ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect 2016; 22(3): 37-62.
7. Stiehm ER, Damrosch DS. Factors in the prognosis of meningococcal infection. Review of 63 cases with emphasis on recognition and management of the severely ill patient. J. Pediatr 1966; 68(3): 457-467.
8. Disease data from ECDC Surveillance Atlas for meningococcal disease. Available at web site:https://ecdc.europa.eu/en/meningococcal-disease/surveillance-and-disease-data/ atlas. Accessed March 20, 2018.
9. Luca V, Gessner BD, Luca C, et al. Incidence and etiological agents of bacterial meningitis among children <5 years of age in two districts of Romania. Eur J Clin Microbiol Infect Dis 2004; 23(7): 523-528.
10. Cordeiro SM, Neves AB, Ribeiro CT, et al. Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil. Trans R Soc Trop Med Hyg 2007; 101(11): 1147-1153.
11. Strelow VL, Miranda ÉJ, Kolbe KR, Framil JV, Oliveira AP, Vidal JE. Meningococcal meningitis: clinical and laboratorial characteristics, fatality rate and variables associated with in-hospital mortality. ArqNeuropsiquiatr 2016; 74(11): 875-880.
12. Tarafdar K, Rao S, Recco RA, Zaman MM. Lack of sensitivity of the latex agglutination test to detect bacterial antigen in the cerebrospinal fluid of patients with culture-negative meningitis. Clin Infect Dis 2001; 33(3): 406-408.
13. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcemia, and Neisseria meningitidis. Lancet 2007; 369(9580): 2196-2210.
14. ***Organización Panamericana de la Salud. Informe Regional de SIREVA II, 2010: datos por país y por grupos de edadsobrelas características de los aislamiento de Streptococccus pneumoniae, Hae-mophilus influenzae y Neisseria meningitidis emprocesos invasores. Available at web site: http://www.paho.org/hq/. Accessed September 20, 2018.
15. SeenaaMA, HeershHR. Meningitis in Sulaimani Pediatric Teaching Hospital: A Retrospective Study. Mustansiriya Medical Journal 2017; 16(2): 13-20.
16. Heckenberg SG, de Gans J, Brouwer MC, et al. Clinical features, outcome, and meningococcal geno-type in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine (Baltimore) 2008; 87(4): 185-192.
17. Franco-Paredes C, Lammoglia L, Hernández I, Santos-Preciado JI. Epidemiology and outcomes of bacterial meningitis in Mexican children: 10-year experience (1993-2003). Int J Infect Dis 2008; 12(4): 380-386.
18. Shapiro ED. Prophylaxis for bacterial meningitis. Med Clin North Am 1985; 69(2): 269-280.
19. ***European Centre for Disease Prevention and Control. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA. Available at web site:https://ecdc.europa.eu/en/publications-data/expert-opinion-introduction-meningo-coccal-b-4cmenb -vaccine-eueea. Accessed September 20, 2018.
Published
2018-12-27
Section
INTERNAL MEDICINE - PEDIATRICS